文献速递免疫规划传染病防控与疫情报告

肺炎球菌结合疫苗加强剂对不列颠哥伦比亚省2003-2018年侵袭性肺炎球菌病预防效果的影响

Effect of pneumococcal conjugate vaccine booster dose on prevention of invasive pneumococcal disease in British Columbia, 2003-2018.
PubMed 文献 · Vaccine · 2025-12-03

本研究基于加拿大不列颠哥伦比亚省2003-2018年18岁以下儿童实验室监测与免疫登记数据,采用泊松回归估计不同疫苗接种状态下的侵袭性肺炎球菌病(IPD)年发病率。结果显示,与未接种相比,基础+加强组aIRR为0.13(95%CI 0.10-0.17),仅基础组为0.32(95%CI 0.22-0.48);基础+加强组较仅基础组发病率低61%(aIRR 0.39,95%CI 0.26-0.60),支持推广2+1全程接种程序。

要点

  • 基础+加强组IPD年发病率为4.6/10万,显著低于未接种组36.1/10万。
  • 基础+加强组较仅基础组IPD发病率降低61%(aIRR 0.39,95%CI 0.26-0.60)。
  • 各年龄组和血清型组中加强剂获益模式一致,支持推广2+1程序。

核心结论

  • 包含加强剂的接种程序与显著更低的IPD发病率相关,支持推广全程基础+加强(2+1)程序以降低儿童IPD负担。

研究设计与样本

  • 基于加拿大不列颠哥伦比亚省2003-2018年18岁以下儿童实验室监测IPD病例与省级免疫登记接种记录,采用泊松回归估计年发病率,按血清型组、年龄和疫苗时期分层计算调整发病率比(aIRR)。

主要发现

  • 共598例IPD病例,53.2%未接种,31.8%接种2-3剂基础+1剂加强,15.1%仅接种1-3剂基础。
  • 年调整发病率每10万为36.1(未接种)、11.6(仅基础)、4.6(基础+加强)。
  • 与未接种相比,基础+加强组aIRR为0.13(95%CI 0.10-0.17),仅基础组为0.32(95%CI 0.22-0.48)。
  • 基础+加强组较仅基础组发病率低61%(aIRR 0.39,95%CI 0.26-0.60)。
  • 各年龄组(<12月、12-23月、2-4岁、5-9岁、10-18岁)和血清型组(PCV7、额外PCV13、非PCV13)模式一致,PCV7(2003-2010)与PCV13(2010-2018)时期aIRR无显著差异。

临床怎么用

  • 支持在儿童免疫规划中推广包含加强剂的全程基础+加强(2+1)接种程序,以降低IPD负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive pneumococcal disease (IPD) remains a major cause of morbidity in children despite the routine use of pneumococcal conjugate vaccines (PCVs) in childhood immunization programs. While the effectiveness of different vaccination schedules is well established, the additional benefit of the booster dose remains unknown. This study estimated the incidence of IPD by vaccination status in children under 18 years of age in British Columbia (BC), Canada, from 2003 to 2018. METHODS: IPD cases were identified through laboratory surveillance and vaccination records obtained from provincial immunization registries. We estimated annual IPD incidence using Poisson regression, with the offset being the population at risk derived from immunization coverage rates. We calculated adjusted incidence rate ratios (aIRRs) stratified by serotype group, age, and vaccine period. RESULTS: Among 598 IPD cases, 53.2 % were unvaccinated, 31.8 % received 2-3 primary doses and 1 booster dose (primary + booster), 15.1 % received 1-3 primary doses (primary only). Annual adjusted incidence per 100,000 was 36.1 (unvaccinated), 11.6 (primary only), and 4.6 (primary + booster). Compared to unvaccinated children, aIRRs were 0.13 (95 % CI: 0.10-0.17) for primary + booster and 0.32 (95 % CI, 0.22-0.48) for primary only. The primary + booster group had a 61 % lower incidence than the primary-only group (aIRR 0.39, 95 % CI: 0.26-0.60). These patterns were consistent across age groups (<12 months, 12-23 months, 2-4 years, 5-9 years, and 10-18 years) and serotype groups (PCV7, additional PCV13, and non-PCV13). No significant differences in aIRR were observed between PCV7 (2003-2010) and PCV13 (2010-2018) eras. CONCLUSIONS: A schedule including a booster dose was associated with a significantly lower incidence of IPD. These findings support promoting the full primary + booster (2 + 1) schedule to reduce IPD burden in children.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chang CY, Nasreen S, Sadarangani M, et al. Effect of pneumococcal conjugate vaccine booster dose on prevention of invasive pneumococcal disease in British Columbia, 2003-2018. Vaccine. 2025. PMID: 41343987. doi:10.1016/j.vaccine.2025.128066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。